Naproxen Should Be NSAID Trial Standard, FDA And Committees Say
This article was originally published in The Pink Sheet Daily
Executive Summary
The agent is excluded from non-steroidal anti-inflammatory drug cardiovascular warnings unanimously recommended by FDA advisory committees reviewing COX-2 inhibitors. FDA’s Temple says naproxen’s safety profile makes the drug suitable as a “reference standard” for the NSAID class.
You may also be interested in...
Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
Merck’s Arcoxia should not be approved based on a comparison to diclofenac in the MEDAL studies, Cleveland Clinic’s Nissen says.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.